Native, human C3 complement component. Glycoprotein composed of two non-identical disulfide-bonded subunits with M.W. of 115 kDa (α) and 75 kDa (β). Present in normal human serum at 1.25 mg/ml. Classical and alternative activation pathways of complement converge at C3 step. Activation via either pathway can result in assembly of C3-cleaving enzymes (C3 convertases) on target surfaces. Both C3 convertases cleave the C3 α-chain at peptide bond 77 resulting in production of C3a (M.W. 9083) and C3b fragments (M.W. 180,000). Released C3a peptide is one of the three complement anaphylatoxins. The nascent C3b fragment can form a covalent ester bond with target surface. This covalent attachment of C3b to target acceptors is required for continuation of complement activation.
| Produktinformationen | |||
|---|---|---|---|
| Form | Liquid | ||
| Formulation | In PBS, pH 7.2. | ||
| Avoid freeze/thaw | Ja | ||
| Biological activity | >3,000 C3H50 units/mg; ≥60% of the C3 activity in normal human serum on a mg/mg basis. | ||
| Purity | ≥95% by SDS-PAGE | ||
| Contaminants | IgG, IgA, IgM, C4, functionally active C5, albumin or ceruloplasmin: ≤trace amounts | ||
| Source | Prepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV. | ||
| CAS-Nummer | 80295-41-6 | ||
| Lager- und Versandinformationen | |||
|---|---|---|---|
| Lagerkategorie | ≤ -70°C | ||
| Ship |
Dry Ice Only
Standard Handling |
||
